Search

Your search keyword '"Vestbo, J"' showing total 5 results
5 results on '"Vestbo, J"'

1. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort.

Author

Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, Pandis I, Bansal AT, Bel EH, Auffray C, Compton CH, Bisgaard H, Bucchioni E, Caruso M, Chanez P, Dahlén B, Dahlen SE, Dyson K, Frey U, Geiser T, Gerhardsson de Verdier M, Gibeon D, Guo YK, Hashimoto S, Hedlin G, Jeyasingham E, Hekking PP, Higenbottam T, Horváth I, Knox AJ, Krug N, Erpenbeck VJ, Larsson LX, Lazarinis N, Matthews JG, Middelveld R, Montuschi P, Musial J, Myles D, Pahus L, Sandström T, Seibold W, Singer F, Strandberg K, Vestbo J, Vissing N, von Garnier C, Adcock IM, Wagers S, Rowe A, Howarth P, Wagener AH, Djukanovic R, Sterk PJ, and Chung KF

Subjects
Adult, Anxiety epidemiology, Asthma drug therapy, Asthma epidemiology, Case-Control Studies, Comorbidity, Cross-Sectional Studies, Depression epidemiology, Europe, Female, Gastroesophageal Reflux epidemiology, Humans, Male, Middle Aged, Nitric Oxide analysis, Prospective Studies, Quality of Life, Severity of Illness Index, Smoking epidemiology, Spirometry, Surveys and Questionnaires, Systems Biology, Adrenal Cortex Hormones administration & dosage, Anti-Asthmatic Agents administration & dosage, Asthma complications, Smoking adverse effects
Abstract

U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach.This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements.Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids.Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of "omic" datasets that are at the core of this systems medicine approach., (Copyright ©ERS 2015.)

Published
2015
Full Text
View/download PDF

3. Integrated care pathways for airway diseases (AIRWAYS-ICPs)

Author

Bousquet, Jean, Addis, A., Adcock, I. M., Agache, I., Agusti, A., Alonso, A., Annesi-Maesano, I., Anto, Josep M., Bachert, C., Baena-Cagnani, C. E., Bai, C., Baigenzhin, A. K., Barbara, Cristina, Barnes, P. J., Bateman, E. D., Beck, L., Bedbrook, Anna, Bel, E. H., Benezet, O., Bennoor, K. S., Benson, M., Bernabeu-Wittel, M., Bewick, M., Bindslev-Jensen, C., Blain, Hubert, Blasi, F., Bonini, M., Bonini, S., Boulet, L. P., Bourdin, Arnaud, Bourret, Rodolphe, Brightling, C. E., Briggs, A. H., Brozek, J. L., Buhl, R., Bush, A., Caimmi, D. P., Calderon, M. A., Calverley, P. M., Camargos, P. A. M., Camuzat, Thierry, Canonica, G. W., Carlsen, K. H., Casale, T. B., Cazzola, M., A.M, Cepeda Sarabia, Cesario, A., Chen, Y. Z., Chkhartishvili, E., Chavannes, Niels H., Chiron, R., Chuchalin, Alexander G., Chung, K. F., Cox, L., Crooks, George, Cruz, A. A., Custovic, Adnan, Dahl, R., Dahlen, S. E., Blay, F. De, Dedeu, Antoni, Deleanu, D., Demoly, Pascal, Devillier, P., Didier, A., Dinh-Xuan, A. T., Djukanovic, R., Dokic, D., Douagui, H. B., Dubakiene, R., Eglin, S., Elliot, F., Emuzyte, R., Fabbri, Leonardo M., Fink-Wagner, A., Fletcher, M., Fokkens, W. J., Fonseca, J. A., Franco, A., Frith, P., Furber, A., Gaga, M., Garces, J., Garcia-Aymerich, Judith, Gamkrelidze, A., Diaz, S. González, Gouzi, Fares, Guzmán, M. A., Haahtela, T., Harrison, D., Hayot, M., Heaney, L. G., Heinrich, J., Hellings, P. W., Hooper, J., Humbert, M., Hyland, M. E., Iaccarino, G., Jakovenko, D., Jardim, J. R., Jeandel, Claude, Jenkins, C., Johnston, S. L., Jonquet, Olivier, Joos, G., Jung, K. S., Kalayci, O., Karunanithi, S., Keil, T., Khaltaev, N., Kolek, V., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Le, Tuyen D., Carlsen, K. C. Lodrup, Louis, R., MacNee, W., Mair, A., Majer, I., Manning, P. J., Keenoy, E. De Manuel, Masjedi, M. R., Melén, E., Gomes, Elisabete Melo, Menzies-Gow, A., Mercier, G., Mercier, Jacques, Michel, J. P., Miculinic, N., Mihaltan, F., Milenkovic, B., Molimard, M., Momas, I., Montilla-Santana, A., Almeida, M. Morais, Morgan, M., N'Diaye, M., Nafti, S., Nekam, K., Neou, A., Nicod, L., O'Hehir, R. E., Ohta, K., Paggiaro, P. L., Palkonen, S., Palmer, S., Papadopoulos, N. G., Papi, A., Passalacqua, G., Pavord, I., Pigearias, B., Plavec, D., Postma, D. S., Price, D., Rabe, K. F., Radier-Pontal, F., Redon, Josep, Rennard, S., Roberts, J., Robine, J. M., Roca, J., Roche, N., Rodenas, F., Roggeri, A., Rolland, C., Rosado-Pinto, J., Ryan, D., Samolinski, B., Sanchez-Borges, M., Schunemann, H. J., Sheikh, A., Shields, K. M., Siafakas, N., Sibille, Y., Similowski, T., Small, I., Sola-Morales, O., Sooronbaev, T., Stelmach, R., Sterk, P. J., Stiris, T., Sud, P., Tellier, V., To, T., Todo-Bom, A., Triggiani, M., Valenta, R., Valero, A. L., Valiulis, A., Valovirta, E., Ganse, E. Van, Vandenplas, O., Vasankari, T., Vestbo, J., Vezzani, G., Viegi, Giovanni, Visier, L., Vogelmeier, C., Vontetsianos, T., Wagstaff, R., Wahn, U., Wallaert, B., Whalley, B., Wickman, M., Williams, D. M., Wilson, N., Yawn, B. P., Yiallouros, Panayiotis K., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zhong, N., Zidarn, M., Zuberbier, T., Bousquet, J., Addis, A., Adcock, I., Agache, I., Agusti, A., Alonso, A., Annesi-Maesano, I., Anto, J. M., Bachert, C., Baena-Cagnani, C. E., Bai, C., Baigenzhin, A., Barbara, C., Barnes, P. J., Bateman, E. D., Beck, L., Bedbrook, A., Bel, E. H., Benezet, O., Bennoor, K. S., Benson, M., Bernabeu-Wittel, M., Bewick, M., Bindslev-Jensen, C., Blain, H., Blasi, F., Bonini, M., Bonini, S., Boulet, L. P., Bourdin, A., Bourret, R., Bousquet, P. J., Brightling, C. E., Briggs, A., Brozek, J., Buhl, R., Bush, A., Caimmi, D., Calderon, M., Calverley, P., Camargos, P. A., Camuzat, T., Canonica, G. W., Carlsen, K. H., Casale, T. B., Cazzola, M., Cepeda Sarabia, A. M., Cesario, A., Chen, Y. Z., Chkhartishvili, E., Chavannes, N. H., Chiron, R., Chuchalin, A., Chung, K. F., Cox, L., Crooks, G., Crooks, M. G., Cruz, A. A., Custovic, A., Dahl, R., Dahlen, S. E., De Blay, F., Dedeu, T., Deleanu, D., Demoly, P., Devillier, P., Didier, A., Dinh-Xuan, A. T., Djukanovic, R., Dokic, D., Douagui, H., Dubakiene, R., Eglin, S., Elliot, F., Emuzyte, R., Fabbri, L., Fink Wagner, A., Fletcher, M., Fokkens, W. J., Fonseca, J., Franco, A., Frith, P., Furber, A., Gaga, M., Garces, J., Garcia-Aymerich, J., Gamkrelidze, A., Gonzales-Diaz, S., Gouzi, F., Guzman, M. A., Haahtela, T., Harrison, D., Hayot, M., Heaney, L. G., Heinrich, J., Hellings, P. W., Hooper, J., Humbert, M., Hyland, M., Iaccarino, G., Jakovenko, D., Jardim, J. R., Jeandel, C., Jenkins, C., Johnston, S. L., Jonquet, O., Joos, G., Jung, K. S., Kalayci, O., Karunanithi, S., Keil, T., Khaltaev, N., Kolek, V., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Le, L. T., Lodrup Carlsen, K. C., Louis, R., Macnee, W., Mair, A., Majer, I., Manning, P., De Manuel Keenoy, E., Masjedi, M. R., Melen, E., Melo-Gomes, E., Menzies-Gow, A., Mercier, G., Mercier, J., Michel, J. P., Miculinic, N., Mihaltan, F., Milenkovic, B., Molimard, M., Momas, I., Montilla-Santana, A., Morais-Almeida, M., Morgan, M., N'Diaye, M., Nafti, S., Nekam, K., Neou, A., Nicod, L., O'Hehir, R., Ohta, K., Paggiaro, P., Palkonen, S., Palmer, S., Papadopoulos, N. G., Papi, A., Passalacqua, G., Pavord, I., Pigearias, B., Plavec, D., Postma, D. S., Price, D., Rabe, K. F., Radier Ponta, F., Redon, J., Rennard, S., Roberts, J., Robine, J. M., Roca, J., Roche, N., Rodenas, F., Roggeri, A., Rolland, C., Rosado-Pinto, J., Ryan, D., Samolinski, B., Sanchez-Borges, M., Schunemann, H. J., Sheikh, A., Shields, M., Siafakas, N., Sibille, Y., Similowski, T., Small, I., Sola-Morales, O., Sooronbaev, T., Stelmach, R., Sterk, P. J., Stiris, T., Sud, P., Tellier, V., To, T., Todo-Bom, A., Triggiani, M., Valenta, R., Valero, A. L., Valiulis, A., Valovirta, E., Van Ganse, E., Vandenplas, O., Vasankari, T., Vestbo, J., Vezzani, G., Viegi, G., Visier, L., Vogelmeier, C., Vontetsianos, T., Wagstaff, R., Wahn, U., Wallaert, B., Whalley, B., Wickman, M., Williams, D. M., Wilson, N., Yawn, B. P., Yiallouros, P. K., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zhong, N., Zidarn, M., Zuberbier, T., Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Department of Allergy and Clinical Immunology, Faculty of Medicine-Transylvania University, Applied Tumor Virology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Ghent University Hospital, Laboratoire d'ingénierie osteo-articulaire et dentaire (LIOAD), Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), iQ4U consultants Ltd, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Pathophysiology and Transplantation, Università degli Studi di Milano = University of Milan (UNIMI), Istituto di Geoscienze e Georisorse, Pavia, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] (LSCE), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Department of Infection, Immunity and Inflammation, Royal Brompton Hospital, Région Languedoc-Roussillon-Midi-Pyrénées, Service de physiologie et explorations fonctionelles [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University Hospital Southampton, Vilnius University [Vilnius], IMIM-Hospital del Mar, Generalitat de Catalunya, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, University Hospitals Leuven [Leuven], University of Edinburgh, Pneumology Department, Marius Nasta Institute of Pneumology, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Monash University [Melbourne], Allergy and Respiratory Diseases, Università degli studi di Genova = University of Genoa (UniGe), Mécanismes moléculaires dans les démences neurodégénératives (MMDN), Université Montpellier 2 - Sciences et Techniques (UM2)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neurophysiologie Respiratoire Expérimentale et Clinique, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), AcademicMedical Center, Oslo University Hospital [Oslo], University of Coimbra [Portugal] (UC), Division of Clinical Immunology and Allergy, University of Naples Federico II = Università degli studi di Napoli Federico II, University of Turku, Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Consiglio nazionale delle ricerche, Instituto di fisiologia clinica, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Service de Pneumologie et Immuno-Allergologie [CHU LIlle], Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), University Hospital of Cologne [Cologne], Çocuk Sağlığı ve Hastalıkları, AII - Amsterdam institute for Infection and Immunity, Pulmonology, Ear, Nose and Throat, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Milan, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), University of Helsinki, University of Genoa (UNIGE), Université de Montpellier (UM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Università degli studi di Napoli Federico II, Groningen Research Institute for Asthma and COPD (GRIAC), Yiallouros, Panayiotis K. [0000-0002-8339-9285], Custovic, Adnan [0000-0001-5218-7071], and Γιάλλουρος, Παναγιώτης

Subjects
Aging, Settore MED/10 - Malattie dell'Apparato Respiratorio, International Cooperation, Respiratory System, Medically Underserved Area, Comorbidity, Disease, Early intervention, Medical and Health Sciences, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Disease control, Risk Factors, Chronic obstructive lung disease, Health care, 030212 general & internal medicine, Rhiniti, media_common, Rhinitis, Environmental exposure, Child health care, 3. Good health, ALLERGIC RHINITIS, Europe, CHRONIC RESPIRATORY-DISEASES, PERFORMANCE PROGRAM, Action plan, SIMULATION, Asthma, Decision Making, European Union, Guidelines as Topic, Humans, Pulmonary Disease, Chronic Obstructive, Quality of Life, Respiration Disorders, World Health Organization, SMOKING, Human, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Chronic respiratory tract disease, DIAGNOSIS, OBSTRUCTIVE PULMONARY-DISEASE, 03 medical and health sciences, Quality of life (healthcare), EUROPEAN-UNION, medicine, MANAGEMENT, media_common.cataloged_instance, European union, Intensive care medicine, business.industry, Public health, Risk Factor, ta3121, Respiration Disorder, Integrated care, 030228 respiratory system, Physical therapy, Clinical Medicine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, SEVERE ASTHMA
Abstract

International audience; The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYS-ICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers).

Published
2014

4. AIRWAY HYPERRESPONSIVENESS AND COPD MORTALITY.

Author

Vestbo, J. and Hansen, E. F.

Subjects
*OBSTRUCTIVE lung diseases, *MORTALITY, *HISTAMINE, *EOSINOPHILIA, *ASTHMA, *SMOKING
Abstract

Background: Smoking and airway lability which is expressed by histamine airway hyperresponsiveness, are known risk factors for development of respiratory symptoms. Smoking is also associated with increased mortality risks. We studied whether airway hyperresponsiveness is associated with increased mortality and whether this risk was independent of smoking and reduced lung function. Methods: We followed up 2008 inhabitants of the communities of Vlagtwedde, Vlaardingen, and Meppel (Netherlands), who had histamine challenge test data from 1964-72 for 30 years. Follow-up was 99% successful (29 patients lost to follow-up) with 1453 participants alive and 526 deaths (246 died from cardiovascular disease, 54 from lung cancer, and 21 from chronic obstructive pulmonary disease (COPD)). Findings: Mortality from COPD increased with more severe hyper-responsiveness relative risks of 3.83 (95% Cl 0.97-15.1), 4.40 (1.16-16.7), 4.78 1.27-18.0), 6.69 (1.71-26.1), and 15.8 (3.72-67.1) were associated with histamine thresholds of 32 g/l, 16 g/l, 8 g/l, 4 g/I, and 1 g/l, respectively compared with no hyperresponsiveness. These risks were adjusted for sex, age, smoking, lung function, body mass index, positive skin tests, eosinophilia, asthma, and city of residence. Interpretation: Increased histamine airway hyper-responsiveness predicts modality from COPD. Although this trend was more pronounced in smokers, an increasing proportion of COPD deaths with increasing hyper-responsiveness was also present among individuals who had never smoked. [ABSTRACT FROM AUTHOR]

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results